JLE

European Journal of Dermatology

MENU

A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma Volume 28, numéro 1, January-February 2018

Illustrations


  • Figure 1

Tableaux

Auteurs
1 Department of Dermatology, CHRU, Tours, France
2 PRES Centre, Val de Loire University, University Francois Rabelais de Tours, Tours, France
3 Department of Dermatology, CHR Le Mans, France
4 Department of Dermatology, CHR Orléans, France
5 INSERM CIC 1415, CHRU Tours, France
6 Inserm U 930, University Francois Rabelais, Tours, France
* Reprints

Background

Some studies have shown that a high neutrophil/lymphocyte ratio (NLR) ≥4 before initiating ipilimumab treatment is an independent prognostic indicator of poor survival in patients with metastatic melanoma (MM).